CD8A and Epstein-Barr virus infection: According to a recent study, nivolumab could clear EBV infection in 4 out of 7 relapsed or refractory HLH patients and restore anti-EBV function in CD8+ T cells.[8] Considering all these factors, the patient agreed to undergo PD-1 blockade immunotherapy.